FLASH radiotherapy: a Blink-and-You'll-Miss-It cancer treatment?
NCT ID NCT05724875
First seen Apr 05, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This study compares a new type of radiation called FLASH, which delivers the dose in less than a second, to standard radiation for treating two common skin cancers: basal cell carcinoma and squamous cell carcinoma. About 60 patients aged 60 and older who cannot have surgery will receive either FLASH or standard radiation. The goal is to see if FLASH causes fewer severe skin side effects while still controlling the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Canton of Vaud, 1011, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FLASH radiotherapy (high-dose-rate radiation delivered in a fraction of a second)
What this could lead to
If it works, FLASH could become a standard treatment for skin cancer, offering fewer side effects and shorter treatment times.
What could go wrong
This is a small, early-phase study with only 60 participants. FLASH is still experimental, and it may not prove safer or as effective as standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.